Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind placebo-controlled trial of crenezumab in prodromal to mild Alzheimer's disease
2016-003288-20Phase 3Terminated
- Sponsor
- Roche
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of crenezumab in Alzheimer's disease (AD), sponsored by Roche. Started Jan 2017; status: terminated.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-003288-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003288-20.